echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Carl June, the father of CAR-T, commented: Beyond cancer, CAR-T successfully treats lupus erythematosus

    Carl June, the father of CAR-T, commented: Beyond cancer, CAR-T successfully treats lupus erythematosus

    • Last Update: 2023-01-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    CAR-T cell therapy is to isolate T cells from the patient's body and genetically engineer them to kill tumor cells
    At present, CAR-T cell therapy has shown strong effects in hematologic malignancies, and the FDA has approved several CAR-T cell therapies for marketing

    On November 23, 2022, Professor Carl June, the "father of CAR-T" and the University of Pennsylvania, published a review article in the journal Cell entitled: CAR-T therapy extends its reach to autoimmune diseases [1], commenting on the very promising effect
    of CAR-T cell therapy in the treatment of patients with the autoimmune disease systemic lupus erythematosus.

    Professor Carl June said that in principle we have always known that CAR-T therapy can be widely used, and the early results of CAR-T treatment for systemic lupus erythematosus are very encouraging

    Professor Carl June

    CAR-T therapy is genetically engineered by each patient's own T cells, collected from the patient's blood, engineered and expanded in the laboratory, and then reinfused back into the patient as a "live-cell drug
    " The world's first CAR-T therapy, Kymriah, was developed by Carl June and his team at the Pennsylvania Medical School and was approved by the FDA in 2017

    There are currently a total of six FDA-approved CAR-T cell therapies for the treatment of cancer
    These CAR-T therapies have revolutionized the treatment of certain B-cell leukemias, lymphoma and other blood cancers, allowing many cancer patients who otherwise had no hope of long-term remission to recover

    From the beginning, scientists believed that CAT-T cells could be engineered and engineered to fight many other diseases
    besides B-cell cancer.
    Dozens of research teams around the world are working on these potential new applications

    In September 2022, Professor Georg Schett's team from the University of Erlangen-Nuremberg (FAU) in Germany published a research paper in Nature Medicine entitled: Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus [2].

    The study reported improvement in all five patients with refractory systemic lupus erythematosus after CAR-T cell therapy, no recurrence at up to 17 months follow-up, and no drug-free remission

    In this clinical trial, five patients (4 women and 1 male) with refractory systemic lupus erythematosus aged 22 years were enrolled between February 14, 2021 and February 2, 2022
    All patients had histologically confirmed glomerulonephritis and heart, lung, and joint involvement
    Although young, all patients have been previously treated with several immunosuppressants, including glucocorticoids, hydroxychloroquine, mycophenolate mofetil, belimab, and others

    The research team treated the five patients
    with modified anti-CD19 CAR-T cells.
    These cells are designed to clear antibody-producing B cells
    by targeting the CD19 protein produced on their surface.

    After 3 months of CAR-T cell administration, all 5 patients with lupus erythematosus experienced sustained improvement in signs and symptoms, including disappearance of nephritis, resolution of arthritis, fatigue, heart valve fibrosis, and lung involvement
    Of note, after treatment, patients could discontinue all immunomodulatory and immunosuppressive drugs, including glucocorticoids and hydroxychloroquine, and all 5 patients achieved drug-free remission

    At long-term follow-up, although B cells reappeared in patients, no relapse was observed in patients up to 17 months, while all patients were still not treated with any systemic lupus erythematosus treatment drugs
    In addition, all patients experienced only mild side effects associated with CAR-T cell therapy, such as fever
    No infection
    occurred at short-term follow-up and during the stage of B-cell hypoplasia.

    Professor Andreas Mackensen (left), Professor Georg Schett (right), and in the center is Thu-Thao V, the world's first patient with systemic lupus erythematosus treated with CAR-T cells.

    Carl June noted in the review that although this CAR-T treatment for lupus erythematosus results still need to be confirmed by larger studies and longer-term follow-up, this result is very promising
    In fact, this study suggests that lupus erythematosus may be a more likely target for CAR-T cell therapy than
    B-cell tumors.

    In addition, the number of disease-driven B cells in lupus erythematosus is much smaller, so CAR-T treatment of autoimmune diseases such as lupus may only require lower doses, which will greatly reduce the immune
    side effects of CAR-T cell therapy.

    Original source:

    Daniel J.
    Baker, Carl H.
    CAR T therapy extends its reach to autoimmune diseases.
    Cell, 2022.

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.